Skip to main content
TipRanks
Go Ultimate75% OFF

Ironwood Pharma (I76) Q3 2026 Earnings Report

3 Followers

DE:I76 Q3 2026 EPS Results

Actual EPS
EUR 0.32
Consensus EPS
EUR 0.29
Beat/Miss
Beat by +EUR 0.03
One Year Ago EPS
EUR 0.21

DE:I76 Q3 2026 Revenue Results

Actual Revenue
EUR 119.12M
Expected Revenue
EUR 108.84M
Beat/Miss
Beat by +EUR 10.27M
YoY Revenue Growth
+9.00%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/05/2026
Time
Before Open
Conference Call
Thursday, November 5, 2026
DE:I76 Upcoming Earnings

Ironwood Pharma's next earnings date is estimated for February 18, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

DE:I76 Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 05, 2026|% Change Since:35.67%|
Earnings Call Sentiment|Positive

The call was strongly positive, characterized by a LINZESS turnaround, more than 35% expected 2026 LINZESS growth, record adjusted EBITDA, raised financial guidance, debt reduction, and continued progress in the apraglutide program. The main limitations were that STARS-2 remains under development with study completion estimated for 2028 and NDA submission supported in 2029, while 2027 financial guidance has not yet been provided.

Company Guidance

Ironwood raised full-year 2026 LINZESS guidance to the range of $1.2 billion-$1.25 billion, representing growth of more than 35% year-over-year, with mid-single-digit demand growth expected for the full year; total revenue guidance is between $485 million and $510 million, adjusted EBITDA is expected to be greater than $350 million, and the company expects to end the year with less than $300 million of debt and gross leverage below 1X. Q4 is expected to be the strongest quarter of the year, and STARS-2 remains on track to activate more than 100 clinical trial sites across 22 countries, with primary study completion estimated for October 2028 to support an NDA submission in 2029; updated STARS Extend clinical results are expected in the first half of 2027.

  • LINZESS Sales Guidance RaisedIronwood raised full-year 2026 LINZESS U.S. net sales guidance to $1.2 billion-$1.25 billion, representing growth of more than 35% year-over-year. The increase was driven primarily by improved net price and mid-single-digit prescription demand growth.
  • Strong LINZESS Third-Quarter and Year-to-Date PerformanceQ3 LINZESS net sales were $325 million, while year-to-date net sales reached $880 million through Q3, already exceeding full-year 2025 net sales. EU TRX demand volume grew 5% year-over-year, and mid-single-digit demand growth is still expected for the full year.
  • Expected Strong Fourth Quarter for LINZESSManagement expects Q4 to be LINZESS's strongest quarter of the year, driven by continued demand, improved net price, the elimination of inflationary rebates across channels, and fewer Medicare Part D patients reaching the catastrophic phase due to the lower list price.
  • LINZESS Maintains Market LeadershipLINZESS remains the U.S. branded leading prescription therapy for both IBS-C and chronic constipation and continues to address the unmet needs of millions of patients. Management stated that the brand is on its way to returning to blockbuster status in 2026 despite being in its 14th year on the market.
  • Broad LINZESS Demand and AccessDemand and utilization were reported across Medicare Part D, commercial, and Medicaid channels. Management said broad access across channels was maintained with AbbVie, and approximately 80% of patients have both an abdominal symptom and constipation.
  • LINZESS Commercial Margin and EfficiencyManagement reported no meaningful changes to commercial margins throughout the year and said guidance implies an 80% margin for the remainder of 2026. The company also stated that the brand remains promotionally sensitive, while investments are being optimized toward tactics and channels with the highest returns on investment.
  • STARS-2 Global Trial ProgressAll planned clinical trial applications for STARS-2 have been submitted to international health authorities and are either under review or approved. Ironwood remains on track to activate more than 100 clinical trial sites across 22 countries, and activated sites have begun recruiting and screening patients.
  • Positive Apraglutide Phase III DataIn the STARS trial, patients receiving once-weekly apraglutide achieved a statistically significant reduction in weekly parenteral support volume versus placebo at week 24, with approximately twice the percentage reduction observed with placebo.
  • Long-Term Apraglutide Treatment FindingsMore than 90% of STARS patients opted to enroll in the STARS Extend long-term extension study, and about three-quarters of those patients remain on treatment, with some receiving apraglutide for up to five years. Patients continued to decrease parenteral support requirements over time, with some gaining incremental days off, including achievement of enteral autonomy.
  • Strong Quarterly Financial ResultsThird-quarter total revenue was $133 million, GAAP net income was $60 million, and adjusted EBITDA reached a record $98 million.
  • Raised Full-Year Financial GuidanceFull-year total revenue guidance was increased to $485 million-$510 million, and adjusted EBITDA guidance was raised to greater than $350 million. Management described this as the second increase to the outlook during 2026.
  • Debt Reduction and Balance-Sheet ProgressIronwood paid down $60 million of its revolving credit facility during the quarter, reducing the outstanding principal balance to $325 million at quarter end. The company expects to end 2026 with less than $300 million of debt and gross leverage below 1X, while retaining resources to advance and prepare for potential commercialization of apraglutide.
  • Liquidity and Capital Allocation FlexibilityThe company ended the quarter with $86 million in cash and cash equivalents and $133 million in collaboration receivables. Management expects operating cash flow to support apraglutide development and commercial launch activities while continuing to delever and evaluate disciplined capital allocation.
  • Leadership Transition PlanTammi Gaskins was appointed Ironwood's next Chief Executive Officer effective January 1, 2027, when Tom McCourt retires. Management expressed confidence in the transition, citing Gaskins's role in establishing LINZESS as the leading brand, driving the 2026 turnaround, and contributing to apraglutide since its inception.
  • Positive Outlook for LINZESS DemandManagement said demand exceeded expectations at the beginning of 2026 and expects strong demand to continue based on current trends, market growth, and maintained broad access across channels. The company also stated that the $136 Medicare Part D Most Favored Nation price for 2027 is in line with expectations and that it is working to sustain and optimize net price across channels.

DE:I76 Earnings History

DE:I76 earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Feb 18, 20272026 (Q4)0.34--0.01――
Nov 05, 20262026 (Q3)0.290.320.2156.52% (+0.12)
Aug 06, 20262026 (Q2)0.290.280.13121.43% (+0.15)
May 07, 20262026 (Q1)0.220.21-0.21204.35% (+0.42)
Feb 25, 20262025 (Q4)-0.06-0.010.02-150.00% (-0.03)
Nov 10, 20252025 (Q3)0.090.210.021050.00% (+0.19)
Aug 07, 20252025 (Q2)0.020.13-0.011500.00% (+0.13)
May 07, 20252025 (Q1)-0.12-0.21-0.03-666.67% (-0.18)
Feb 27, 20252024 (Q4)0.080.02-0.01300.00% (+0.03)
Nov 07, 20242024 (Q3)0.060.020.08-77.78% (-0.06)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed